Ian A. Cook, Md Dlfapa Fctmss Email and Phone Number
Ian A. Cook, Md Dlfapa Fctmss work email
- Valid
- Valid
- Valid
Ian A. Cook, Md Dlfapa Fctmss personal email
Ian A. Cook, Md Dlfapa Fctmss phone numbers
Ian A. Cook, Md Dlfapa Fctmss is a CEO/Founder/Director, Los Angeles TMS Institute. Co-Founder & Past-CEO, HeartCloud.io. UCLA Professor Emeritus. CMO/SVP NeuroSigma. at Los Angeles TMS Institute, Inc.. They possess expertise in neuroscience, clinical research, psychiatry, healthcare, treatment and 42 more skills. Colleagues describe them as "Dr. Cook has mastered the fusion of academic ingenuity, humility and collegial synergy. Present and future healthcare professionals can increase their positive influence by following his example."
Los Angeles Tms Institute, Inc.
View-
Ceo, FounderLos Angeles Tms Institute, Inc. Jul 2018 - PresentProviding advanced treatment options for depression and other disorders, with interventions including Transcranial Magnetic Stimulation (TMS), the SAINT protocol, and ketamine. By referral only. www.LATMS.com -
Vice President, Founding Board MemberFoundation For The Advancement Of Clinical Tms Jan 2023 - PresentBrentwood, Tn, Us -
Professor Emeritus, Dept Of Psychiatry & Biobehavioral Sci, David Geffen Sch Of Medicine At UclaUcla Health System Jul 1995 - PresentLos Angeles, Ca, UsProfessor Emeritus July 2018 - Professor-in-Residence July 2010 - June 2018Associate Professor-in-Residence July 2003 - June 2010Assistant Professor-in-Residence July 1996 - June 2003Instructor July 1995 - June 1996* Innovating through translational neuroscience research* Promoting and providing evidence-based excellence in patient care* Teaching across multiple levels, from Continuing Education programs, to residents, medical students, undergraduates, and primary school students* Leading through administrative roles at the School of Medicine, in the Semel Institute, and in the Department of Psychiatry and Biobehavioral Sciences * See http://www.IanCook.com for details -
Chief Translational Innovation Officer, Semel Institute For Neuroscience And Human Behavior At UclaUcla Health System Jul 2017 - Jun 2018Los Angeles, Ca, UsFacilitate and accelerate the identification, development, and commercialization of discoveries from the Semel Institute -
Attending PhysicianUcla Health System Jul 1994 - Jun 2018Los Angeles, Ca, UsPatient care for mental health -
Founding Chief, Transcranial Magnetic Stimulation ServiceUcla Health System May 2009 - May 2014Los Angeles, Ca, UsFounded this clinical service at UCLA, bringing this form of therapeutic neuromodulation to the UCLA community -
Chief Resident, Consultation-Liaison PsychiatryUcla Health System Jul 1993 - Jun 1994Los Angeles, Ca, Us -
Resident In PsychiatryUcla Health System 1990 - 1994Los Angeles, Ca, Us -
Chief Medical Officer, Senior Vice President (On Leave)Neurosigma, Inc. Feb 2014 - PresentNeuroSigma, Inc., is a Los Angeles-based life sciences company, established to develop neuromodulation technologies with the potential to transform medical practice and patients’ lives. The clinical focus has been neurological and neuropsychiatric disorders.Trigeminal Nerve Stimulation (TNS) is unique among neuromodulation therapies because it can be delivered via a non-invasive external trigeminal nerve stimulation (eTNS™) system, or a minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system. NeuroSigma is investigating TNS as a treatment for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Traumatic Brain Injury (TBI), and a rare, orphan disorder, Lennox-Gastaut Syndrome (LGS). One of the inventors of the core IP around TNS, I was Senior Medical Advisor to the company before becoming CMO and SVP in February 2014.Links to some representative activities:* PTSD http://t.co/7vU11T3uHB :: http://ucla.in/1PerckG :: http://bit.ly/22wxPve* ADHD http://mdgdgt.com/1lvcBu4* TBI http://bit.ly/1RJwsChCurrently on leave
-
Member, Board Of DirectorsClinical Tms Society 2013 - PresentFresno, California, Us"By pooling together resources and experience, the Clinical TMS Society aims to optimize the administration of TMS, develop novel indications for treatment, expand insurance coverage, and increase public awareness of TMS around the world." http://www.ClinicalTMSSociety.orgCo-Chair, Legal, Business, and Ethics Committee 2017 - present -
Co-FounderHeartcloud, Inc. 2018 - 2024Los Angeles, California, UsCEO and Chairman, Board of Directors 2018 - 2023.CMO 2023 - 2024HeartCloud.io unleashes the rich data collected via wearables and at-home sensors, and provides Insights into health and fitness for clinicians to provide higher quality remote care, through Remote Physiologic Monitoring and Remote Therapeutic Monitoring. HeartCloud for Health Practices (practices.heartcloud.io) gives providers access to the data with visualizations that cut through the noise and guide them to the key information - for better informed decisions, made more efficiently and profitably.https://practices.heartcloud.io -
Psychiatrist, Mood Disorders And Tms Programs, Gla Va HealthU.S. Department Of Veterans Affairs Sep 2016 - Jun 2018Washington, Dc, UsWorking to deliver and improve mental health care for our Veterans -
Director, Ucla Neuromodulation Scholars Training ProgramUcla Jan 2014 - Jun 2018This program trains psychiatrists to provide state-of-the-art neuromodulation treatments, focusing on the principles and practice of FDA-approved neuromodulation systems and investigational approaches that are in research and development. http://TMSLosAngeles.com/forms/NSTPCallForApplicants.pdfDavid Krantz, MD, PhD, is our inaugural Scholar
-
Professor-In-ResidenceUcla Department Of Bioengineering Jul 2013 - Jun 2018Teaching and establishing research collaborations among groups at UCLA, with a focus on neuromodulation and bioelectrical signals.
-
Director, Ucla Depression Research & Clinic ProgramSemel Institute For Neuroscience And Human Behavior At Ucla 2007 - Jun 2018Los Angeles, Ca, UsImprove care for depression by (a) developing and improving new treatments such as new medications and neuromodulation methods (e.g., trigeminal nerve stimulation, transcranial magnetic stimulation (TMS)), (b) improving the use of current interventions such as using biomarkers to guide treatment planning, (c) catalyzing collaborative research in depression intramurally at UCLA and through extramural research partnering, (d) providing public education on depression and other mood disorders (twitter @moodresearch) -
Attending PsychiatristSemel Institute For Neuroscience And Human Behavior At Ucla Jul 1994 - Jun 2018Los Angeles, Ca, UsRenamed the UCLA Resnick Neuropsychiatric Hospital in 2004 -
Associate Director, Ucla Laboratory Of Brain, Behavior And PharmacologyUcla Semel Institute For Neuroscience And Human Behavior 1995 - 2018Translational neuroscience research
-
Chair Of The Faculty And Faculty Executive CommitteeDavid Geffen School Of Medicine At Ucla Sep 2011 - Sep 2013Elected Representative of the School's Faculty for shared governance.
-
Chief Of StaffResnick Neuropsychiatric Hospital At Ucla Jul 2011 - Jun 2013
-
Joanne And George Miller And Family Chair In Depression ResearchUcla Brain Research Institute May 2008 - Apr 2011Develop biomarkers to help guide the optimal use of existing treatments, and develop new treatments for mood disorders
-
Member, Executive Committee On Practice GuidelinesAmerican Psychiatric Association 2002 - 2008Washington, Dc, UsDevelopment and dissemination of evidence-based practice guidelines -
Member, Steering Committee On Practice GuidelinesAmerican Psychiatric Association 1994 - 2008Washington, Dc, Us -
Chair, Psychiatry Department Curriculum CommitteeDavid Geffen School Of Medicine At Ucla 2005 - 2007Oversee and coordinate the didactic program for Residents in Psychiatry at UCLA
-
Member, California Advisory BoardBest Buddies International 1996 - 2005Miami, Fl, Us -
Nimh Research Fellow, Psychobiology Of Major Psychiatric And Psychosomatic DisordersUcla Neuropsychiatric Institute And Hospital Jul 1993 - Jun 1996T32 MH17140
Ian A. Cook, Md Dlfapa Fctmss Skills
Ian A. Cook, Md Dlfapa Fctmss Education Details
-
Yale School Of MedicineMedicine -
Princeton UniversityEecs & Bioengineering
Frequently Asked Questions about Ian A. Cook, Md Dlfapa Fctmss
What company does Ian A. Cook, Md Dlfapa Fctmss work for?
Ian A. Cook, Md Dlfapa Fctmss works for Los Angeles Tms Institute, Inc.
What is Ian A. Cook, Md Dlfapa Fctmss's role at the current company?
Ian A. Cook, Md Dlfapa Fctmss's current role is CEO/Founder/Director, Los Angeles TMS Institute. Co-Founder & Past-CEO, HeartCloud.io. UCLA Professor Emeritus. CMO/SVP NeuroSigma..
What is Ian A. Cook, Md Dlfapa Fctmss's email address?
Ian A. Cook, Md Dlfapa Fctmss's email address is ic****@****cla.edu
What is Ian A. Cook, Md Dlfapa Fctmss's direct phone number?
Ian A. Cook, Md Dlfapa Fctmss's direct phone number is +131082*****
What schools did Ian A. Cook, Md Dlfapa Fctmss attend?
Ian A. Cook, Md Dlfapa Fctmss attended Yale School Of Medicine, Princeton University.
What skills is Ian A. Cook, Md Dlfapa Fctmss known for?
Ian A. Cook, Md Dlfapa Fctmss has skills like Neuroscience, Clinical Research, Psychiatry, Healthcare, Treatment, Mental Health, Medicine, Medical Education, Pharmacology, Psychopharmacology, Life Sciences, Clinical Trials.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial